Company: BLUWU
Filing Date: 2025-03-31
Form Type: S-1/A
Source: 0001641172-25-001410
Chunk: 202

Company: Blue Water Acquisition Corp. III
Filing Date: 2025-03-31
Form: S-1/A
Chunk 202
---
 future. Prof. Coulson edits the leading specialist ecological journal (Ecology Letters) and has won numerous awards for his research and teaching. Prof. Coulson obtained his undergraduate degree in Biology from the University of York, and a PhD from Imperial College, London.We believe Prof. Coulson is qualified to serve on our Board of Directors due to his experience as an academic and research leader.

Dr. Trevor L. Hawkinswill serve as a member of our board of directors upon the effectiveness of the registration statement of which this prospectus forms a part. Dr. Hawkins has built a recognized career in the healthcare industry over the past 25 years spanning business, academic innovation and as an entrepreneur. Dr. Hawkins is a former director of the U.S. Department of Energy’s Human Genome Project and has diverse commercial and managerial experience at leading global companies. Dr. Hawkins currently serves on several boards in the life science industry. In April 2024, Dr. Hawkins was appointed to the Supervisory Board of Genomtec S.A., a public molecular diagnostics company based in Poland. He has been a member of the Board of Directors of Resistell AG, a medical technology company, since December 2023, and is also a member of the Science Advisory Boards of Noscendo GmbH and lifespin GmbH. Since January 2016, Dr. Hawkins has served as an Operating Advisor to GreyBird Ventures LLC, a venture capital firm focused on medical diagnostic solutions. Previously, Dr. Hawkins has held several senior executive roles at HP, GE, Siemens Healthcare and Philips. He was also a successful entrepreneur building and selling a diagnostic company based in Shanghai & San Francisco. Dr. Hawkins obtained a B.Sc. at the University of Sussex in the United Kingdom and completed a Ph.D. in Biochemistry from the Laboratory of Molecular Biology, Cambridge in 1993. We believe Dr. Hawkins’ experience as an entrepreneur, academic leader and business leader with diverse experience in global healthcare qualifies him to serve on our Board of Directors.

Ish S. Dugalwill serve as a member of our board of directors upon the effectiveness of the registration statement of which this prospectus forms a part. Mr. Dugal has 20 years of venture capital and private equity investment experience with a focus on AI, software, and deep tech. He is the co-founder and a Managing Partner at IronArc Ventures, a venture capital firm based in Silicon Valley, and serves as the CIO of GoldenArc, a private investment firm. Mr. Dugal has led investments in companies like Anth